Drunk Elephant
Clinical Is a Claim. What's Your Evidence?
Prestige beauty grew 8 percent in Q1 2024. Mass grew 4 percent.
In this issue
The Quarter in Brand Authority
The Brand Worth Watching — Drunk Elephant
The Vocabulary Shift
Category Signals
The Blind Spot
The Question
The growth is real, but its composition is more instructive than the headline. The top gainer in prestige skincare was body spray, with sales nearly tripling year over year. Face serums were second, driven specifically by clinical brand launches. The category is growing because two very specific things are resonating: scent-forward body care at accessible prestige price points, and clinical ingredients with expert credentials behind them. Everything else is competing for a shrinking share of attention.
The Sephora Kids moment broke in January and is still reverberating. Children as young as eight are purchasing Drunk Elephant products formulated with acids and actives their skin cannot tolerate. Drunk Elephant's sales jumped 77 percent year over year, and its Protini Moisturizer became the number one moisturizer in the US six years after its release. None of this happened because Drunk Elephant went after a younger consumer. It happened because TikTok's algorithm does not distinguish between a 12-year-old and a 32-year-old watching a skincare routine. The brand is benefiting from the tailwind. The question no one is asking yet is what happens when the tailwind reverses and the adults who built the brand's original authority no longer see themselves in it.
Sol de Janeiro is convincing a prestige consumer to spend $19 on a body mist the same way she spends $300 on a fragrance: as an act of identity, not hygiene. The brand expanded to Ulta Beauty this year after eight years as a Sephora exclusive. That decision will generate significant revenue and will cost something harder to quantify: the sense that it belongs to a specific retail world. What bears watching is whether the brand can hold its aspirational positioning as it becomes ubiquitous.
Color cosmetics is growing through product hybridization rather than trend-chasing. The lip segment grew 19 percent in prestige, driven by a format that did not exist five years ago: the lip oil, the tinted balm, the product that delivers color with a skincare benefit story attached. This is not a trend. It is a structural repositioning of the color category toward efficacy as the primary purchase justification. Brands still selling color as pure performance are finding the consumer increasingly skeptical that those things alone justify the price.
Tiffany Masterson founded Drunk Elephant in 2013 with a very specific philosophy: the Suspicious Six -- fragrance, essential oils, silicones, chemical sunscreens, drying alcohols, and SLS/SLES -- were the ingredients responsible for most skin problems, and removing them would let the skin function as it is meant to. That was a clinical claim dressed in a playful brand. The combination was genuinely differentiated in 2013, when clean beauty was barely a vocabulary and efficacy at accessible prestige price points was largely untested.
By 2019, Shiseido paid $845 million for it. The brand was doing approximately $120 million in annual sales. Distribution expanded aggressively. Sales nearly doubled.
What is happening in early 2024 is something Drunk Elephant did not plan and cannot entirely control. Gen Alpha discovered the brand on TikTok and turned it into a collecting object. By January 2024, Sephora employees were managing situations where ten-year-olds were leaving the store with $70 moisturizers formulated with concentrations of retinol and AHAs their skin had no use for.
The sales numbers look extraordinary. A 77 percent year-over-year increase. The Protini Moisturizer at number one nationally. Three hundred percent growth in social media followers. From the outside, this reads as a brand at the height of its authority. It is not. It is a brand sitting on a borrowed tailwind, and the borrowing has a cost.
The cost is the original consumer. Drunk Elephant was built for millennials and Gen X who wanted skin that functioned well, not skin that looked good in a haul video. Those consumers are watching their brand become a tween status symbol, and some of them are already stepping away.
The deeper problem is structural. Drunk Elephant's authority rested on a specific claim -- these are the ingredients that harm skin, and we have removed them -- that required the brand to be taken seriously as a skincare resource, not as a collectible. You cannot be both a clinical skincare brand and the brand eight-year-olds are buying because it photographs well.
The question the category should be asking: when a clinical skincare brand becomes a cultural phenomenon among consumers who cannot use it properly, is that growth or erosion?
The vocabulary entering this quarter: skinification. The word is appearing in trade press, in analyst reports, in brand copy for makeup launches that now lead with skin benefits rather than coverage or color. Circana used the term explicitly in its Q2 2024 reporting. When Circana names a term, it has crossed from brand vocabulary into category vocabulary. That crossing is diagnostic: it means the term has moved from a competitive differentiator to a category expectation. The brands that built their identity around skin-first color before the category had a name for it are now ahead. The brands arriving now with skinification copy are arriving late.
Exiting: barrier. The term had a moment -- it entered the category in 2022 as a specific, clinical concept related to the skin's moisture barrier function. By Q2 2024 it is on packaging for every moisturizer at every price point. When a clinical term appears on a mass-market product it has completed its journey from signal to noise. Any brand still leading with barrier as its primary claim is using retired vocabulary.
Skincare, fragrance, color cosmetics, hair, and wellness signals tracked across observation, validation, and forecast.
Skincare — Clinical Vocabulary Commodifying
What Q2 makes visible is that clinical is now everywhere with no shared definition. Some brands mean dermatologist-developed; others mean ingredient-forward; others mean white packaging. Validation: Augustinus Bader is projecting 40 percent growth this year while the broader prestige skincare category moderates. It has TFC8. The brands borrowing clinical language without that architecture are growing more slowly. Forecast: by Q1 2025, clinical is table stakes. Brands that have already moved to the named mechanism underneath will be ahead.
Fragrance — Concentration Trading Up
Running parallel to the body mist moment, a second behavior is visible: the consumer who entered fragrance through body mists is asking what comes next. Prestige fragrance grew 12 percent in H1 2024, led by higher concentrations. Parfums grew 43 percent for the full year. Validation: Circana noted in March 2024 that consumers are simultaneously trading up to pricier fragrance products and spending more on lower-priced body sprays, a polarization describing a market sorting into two distinct tiers. Forecast: the fragrance consumer will bifurcate. One segment stays in body mist territory. The other moves into higher concentrations as a considered investment.
Color Cosmetics — Lip as Authority Proxy
The consumer is using lip as the test case for the skinification thesis. Validation: lip oils and tinted balms are outselling traditional lipstick formats in prestige, a reversal of the category's historical hierarchy. The winning products have documented skincare actives at accessible prestige price points. Forecast: lip's outperformance will moderate by 2025 as the consumer works through her collection. The brands that built proof architecture in lip will have demonstrated their model to a consumer who will apply the same expectation to adjacent color categories.
Hair — Scalp Skinification Accelerating
The skinification of scalp care is the primary growth driver in prestige hair this quarter. Validation: leave-in scalp treatments up 51 percent and scalp serums up 38 percent in Europe H1 2024. Forecast: within 18 months, every major prestige haircare brand will have a scalp line. The brands with genuine dermatological credibility will differentiate. The brands arriving to follow the trend will commodify scalp positioning.
Wellness — Wellness Reaching Mass Retail
Wellness is completing its migration from specialty retail to mass. Goop's diffusion line Good.Clean.Goop entered Target heading into 2024. Validation: major mass retailers were prioritizing wellness lines in early 2024, the signal that a category has crossed from niche to mainstream. Forecast: as wellness reaches mass, the term begins the same commodification arc as clean. Premium wellness brands with specific, verifiable health claims will survive. Brands that built authority on wellness vocabulary alone will find that vocabulary available at every price point within two years.
The category has spent the past 18 months analyzing Drunk Elephant's decline through the lens of a brand that lost its core consumer to a younger one. That is accurate but incomplete.
The trade conversation in Q2 2024 is almost entirely organized around the female consumer: body mists, skincare routines, lip hybrids, Rare Beauty's blush. Men's fragrance grew 19 percent year over year on Amazon between 2023 and 2024, outpacing women's fragrance at 15 percent and the fragrance category overall at 14 percent. Men aged 18 to 34 are twice as likely to consider buying beauty products from Sephora in 2024 as they were in 2020. Sixty-eight percent of Gen Z men in the US used facial skincare in 2024, up from 42 percent in 2022. The category growing fastest among the demographic nobody is designing for is not a footnote. It is the most underleveraged position in prestige beauty at this moment. The brands building genuine authority with the male consumer now -- not through gendered packaging or performative masculinity, but through the same clinical proof architecture that is winning with women -- are entering a space before it floods with entrants who will arrive when the trade coverage does.
Your brand has a clinical positioning, or is considering one. What does that actually mean in your specific case -- the patented process, the peer-reviewed study, the dermatologist who has used your products for five years and can speak to outcomes?
If the answer is a list of clean ingredients and a results-oriented tone of voice, that is not a clinical positioning. That is a description. Something is sitting between where you are and where the brand needs to go. What is it?